FULL ESTIMATED COST

ENTRY SESSION 0.21 0.21

FILE 'REGISTRY' ENTERED AT 16:24:12 ON 16 APR 2005 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 APR 2005 HIGHEST RN 848629-85-6 DICTIONARY FILE UPDATES: 15 APR 2005 HIGHEST RN 848629-85-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at: http://www.cas.org/ONLINE/DBSS/registryss.html

Uploading C:\Program Files\Stnexp\Queries\10-624659z.str

10/624659 Page 3

```
chain nodes :
14 15 16 17 18 19 20 21 22 23 24 25 26
                                                    29 30 31 32 37 38
                                             27
                                                 28
39 43 44 45 50
ring nodes :
1 2 3 4 5 6 7 8
                     9
                       10 11
                              12
chain bonds :
2-14 3-37 4-7 5-50 6-17 10-20
                              14-15 14-16 17-18 17-19 21-22 21-32 22-23
22-24 25-26 25-27 27-28 29-30 30-31 38-39 43-44 44-45
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
3-37 5-50 22-23 22-24 25-26 25-27 27-28 29-30 30-31 38-39 44-45
exact bonds :
2-14 4-7 6-17 10-20 14-15 14-16 17-18 17-19 21-22 21-32 43-44
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
isolated ring systems :
containing 1 : 7 :
```

G1:[\*1],[\*2]

G2: [\*3], [\*1], [\*2], [\*4], [\*5]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 37:CLASS 38:CLASS 39:CLASS 43:CLASS 44:CLASS 45:CLASS 50:CLASS

10/624659 Page 4

## STRUCTURE UPLOADED L1

=> d

L1 HAS NO ANSWERS

STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful FULL SEARCH INITIATED 16:24:30 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 300 TO ITERATE

300 ITERATIONS 100.0% PROCESSED SEARCH TIME: 00.00.01

10 ANSWERS

10 SEA SSS FUL L1 L2

=> fil caplus

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION FULL ESTIMATED COST 161.33 161.54

FILE 'CAPLUS' ENTERED AT 16:24:33 ON 16 APR 2005 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Apr 2005 VOL 142 ISS 17 FILE LAST UPDATED: 15 Apr 2005 (20050415/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 12

L3 13 L2

=> d ibib abs hitstr tot

L3 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2005 ACS ON STN ACCESSION NUMBER: 2004:715215 CAPLUS DOCUMENT NUMBER: 141:376044

DOCUMENT NUMBER: TITLE:

141:376044
Rydrogen Bonding Interactions of Covalently Bonded
Fluorine Atoms: From Crystallographic Data to a New
Angular Function in the GRID Force Field
Carosati, Emanuele: Sciabola, Simone: Cruciani,
Gabriele AUTHOR (S):

Gabriele Laboratory for Chemometrics and Cheminformatics, Department of Chemistry, University of Perugia, Perugia, 1-6123, Italy Journal of Medicinal Chemistry (2004), 47(21), CORPORATE SOURCE:

SOURCE:

SOURCE:

Journal of Medicinal Chemistry (2004), 47(21),
5114-5125
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER:
American Chemical Society
Journal
LANGUAGE:
AB Through the years the GRID force field has been tuned to fit exptl.
observations in crystal structures. This paper describes the
determination of the
hydrogen bonding pattern for organic fluorines based on an exhaustive
inspection of the Protein Data Bank. All the PDB complexes, whose

protein
structures have cocrystd. fluorine-containing ligands, were examined and
geometrically inspected. By applying statistics, the hydrogen bonding
geometry was described as a distribution function of the angle at the
fluorine: a new specific angular function was consequently defined and
inserted in the program GRID to estimate the effect of fluorine hydrogen

bonds
on the ligand-protein binding. All the fluorine-containing ligands
collected
from the PDB were docked within their corresponding protein binding

sites:
introducing the fluorine hydrogen bonding contribution improves the results of the docking expts. in terms of accuracy and ranking.

introducing the fulcrine hydrogen bonding contribution improves the results of the docking expts. in terms of accuracy and ranking. 782501-49-9

RE: BSU (Biological study) (modeling hydrogen bonding interactions of covalently bonded fluorine atoms in protein ligands) 782501-49-9

CaPLUS 3-Pyridineheptanoic acid, 4-(4-fluorophenyl)-β,δ-dihydroxy-5-(methoxymethyl)-2,δ-bis(1-methylethyl)- (9CI) (CA INDEX NAME)

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR

CH2-CH2-CH-CH2-CH-CH2-CO2H

L3 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN ACCESSION NUMBER: 2002:97696 CAPLUS DOCUMENT NUMBER: 137:72537

TITLE:

Discovery of 5-Hydroxyalkyl-4-phenylpyridines as a

AUTHOR(S):

Class of Glucagon Receptor Antagonists
Ladouceur, Gaetan H.; Cook, James H.; Doherty,
Elizabeth M.; Schoen, William R.; MacDougall, Margit
L.; Livingston, James N.
Department of Chemistry Research, Bayer Research
Center, West Haven, CT, 06516, USA
Bioorganic & Medicinal Chemistry Letters (2002),
12(3), 461-464
CODEN: BMCLES; ISSN: 0960-894X
Elsevier Science Ltd.

CORPORATE SOURCE:

SOURCE:

PUBLISHER:

DOCUMENT TYPE: LANGUAGE:

Doublish
S-Hydroxyalkyl-4-phenylpyridines have been identified as a novel class of
glucagon antagonists with potential utility for the treatment of

A lead structure with moderate activity was discovered through a high throughput screening assay. Structure-activity relationships led to the discovery of a potent antagonist, IC50=0.11 μM, more than 60-fold improvement over the lead structure. 124663-72P

REFERENCE COUNT: THIS

THERE ARE 30 CITED REFERENCES AVAILABLE FOR

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L3 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN (Continued) RECORD. ALL CITATIONS AVAILABLE IN THE RE

L3 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN ACCESSION NUMBER: 2002:63497 CAPLUS DOCUMENT NUMBER: 136:102298

136:102298
Preparation of substituted pyridines
Norbert, Lui: Panskus, Hans: Schnatterer, Albert
Bayer A.-G., Germany
Jpn. Kokal, Tokkyo Koho, 5 pp.
CODEN: JKXKAF
Patent TITLE: INVENTOR(S):

PATENT ASSIGNEE(S): SOURCE:

DOCUMENT TYPE:

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

DATE 20010605 PATENT NO. KIND DATE APPLICATION NO. JP 2002020372 A2 A1 20020123 JP 2001-169465 DE 10111874 PRIORITY APPLN. INFO.: 20011213 DE 2001-10111874 DE 2000-10028141 20010313 20000608 DE 2001-10111874 A 20010313

> DE 2000-10028414 A1 20000608

OTHER SOURCE(S): CASREACT 136:102298; MARPAT 136:102298

Title compds. I (R1, R5 = C1-10 alkyl, C6-10 aryl; R2, R4 = H, C1-10 alkyl, CN, CO2R6; R6 = C1-10 alkyl; R3 = H, C1-10 alkyl, (un)substituted C6-10 aryl) are prepared by reaction of 1,4-dihydropyridine II (R1-R5 = C1-10 aryl) are prepared by reaction of 1,4-dihydropyridine II (R1-R5 = C1-10 aryl) are prepared by reaction of 1,4-dihydropyridine II (R1-R5 = C1-10 aryl) are prepared by reaction of 1,4-dihydropyridine II (R1-R5 = C1-10 aryl) are prepared by reaction of 1,4-dihydropyridine II (R1-R5 = C1-10 aryl) are prepared by reaction of 1,4-dihydropyridine II (R1-R5 = C1-10 aryl) are prepared by reaction of 1,4-dihydropyridine II (R1-R5 = C1-10 aryl) are prepared by reaction of 1,4-dihydropyridine II (R1-R5 = C1-10 aryl) aryly are prepared by reaction of 1,4-dihydropyridine II (R1-R5 = C1-10 aryl) aryly are prepared by reaction of 1,4-dihydropyridine II (R1-R5 = C1-10 aryl) aryly ar

as I) with Me nitrite in the presence of acids containing <20% oxidizing components. 4-(4-Fluorophenyl)-2,6-diisopropyl-3,5-di(methoxycarbonyl)-1,4-dihydropyridine was oxidized with Me nitrite in the presence of HCl

10/624659 Page 6

ANSWER 3 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN (Continued) 60° to give 98% 4-(4-fluorophenyl)-2,6-diisopropyl-3,5-di(methoxycarbonyl)pyridine.
122549-42-2P

IT 122549-42-2P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation) (preparation of substituted pyridines)

RN 122549-42-2 CAPLUS

CN 3,5-Pyridinedicarboxylic acid,
4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-,
dimethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(prepn. of substituted biphenyls as glucagon receptor antagonists)
RN 124863-79-2 CAPLUS
CN 3,5-Pyridinedicarboxylic acid,
4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-,
diethyl ester (9CI) (CA INDEX NAME)

202857-49-6P IT 202857-49-69
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted biphenyls as glucagon receptor antagonists)
RN 202857-49-6 CAPLUS
CN 3-Pyridinecarboxylic acid,
4-(4-flucrophenyl)-5-(1-methoxyethyl)-2,6-bis(1-methylethyl)-, methyl ester (9CI) (CA INDEX NAME)

REFERENCE COUNT: THIS 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR

FORMAT

RECORD. ALL CITATIONS AVAILABLE IN THE RE

```
L3 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN ACCESSION NUMBER: 2001:278024 CAPLUS
DOCUMENT NUMBER:
TITLE:
                                           134:311111
                                           134:31111
Preparation of substituted biphenyls as glucagon receptor antagonists
Schoen, William R.; Ladouceur, Gaetan H.; Cook, James H., II; Lease, Timothy G.; Wolanin, Donald J.;
INVENTOR (S):
Kramss.
                                           Richard H.; Hertzog, Donald L.; Osterhout, Martin H.
Bayer Corporation, USA; Bayer A.-G.
U.S., 136 pp.
CODEN: USXXXAM
PATENT ASSIGNEE(S):
DOCUMENT TYPE:
LANGUAGE:
                                           Patent
                                           English
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
                                                                            APPLICATION NO.
        PATENT NO.
                                           KIND
                                                       DATE
                                                                                                                    DATE
US 6218431
PRIORITY APPLN. INFO.:
                                            В1
                                                       20010417
                                                                            US 1997-904119
US 1997-904119
                                                                                                                    19970731
OTHER SOURCE(S):
                                           MARPAT 134:311111
```

AB Substituted biphenyls I [Rla, Rlb = alkyl; R2 = alkyl with substituents from 1 to 3 of SR7; R7 = Ph, or substituted Ph wherein the substituents are independently 1-5 of halogen, trifluoromethyl, alkyl, alkoxy, nitro, cyano, hydroxyl; R3 = alkyl with substituents of 1-2 hydroxyl groups: G represents a substituent selected from the group consisting of halogen, alkyl, OR4 with R4 = H, alkyl; y = 0-31, glucagon receptor antagonists. E.g., reduction of 2-cyclopentyl-6-ethyl-4-(4-fluorophenyl)-3-(3-trifluoromethylbenzyloxymethyl)pyridine-5-carboxylic acid Et ester with Lidlid gave 76.5%
2-cyclopentyl-6-ethyl-4-(4-fluorophenyl)-5-hydroxymethyl-3-(7-trifluoromethylbenzyloxymethyl)pyridine.

IT 124863-79-2P
RL: BRC (Biological activity or effector, except adverse); BSU
(Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

L3 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2005 ACS ON STN ACCESSION NUMBER: 1998:105938 CAPLUS DOCUMENT NUMBER: 128:167354 Preparation 128:167354
Preparation of substituted pyridines and biphenyls as anti-hypercholesteremic, anti-hyperlipoproteinemic

and

anti-hyperglycemic agents
Schmidt, Gunter: Angerbauer, Rolf; Brandes, Arndt;
Muller-Gliemann, Matthias; Bischoff, Hilmar; Schmidt,
Delf; Wohlfeil, Stefan; Schoen, William R.; INVENTOR (S):

Ladouceur,

Gaetan H.; Cook, James H., II; Lease, Timothy G.; Wolanin, Donald J.; Kramss, Richard H.; Hertzog, Donald L.; Osterhout, Martin H. Bayer Corporation, USA: Bayer Aktiengesellschaft PCT Int. Appl., 431 pp. CODEN: PIXXD2
Patent

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE: LANGUAGE: English

LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PAT	ENT	NO.			KIN	D	DATE			APP	LI	CAT	ION	NO.		D.	ATE		
WO	9804	528			A2		1998	0205		wo	19	97-1	JS 1 3	248		19970729			
WO	9804	528			A3		1999	1111								-			
	W:																		
								GH,											
		LC,	LK,	LR,	LS,	LT,	LU,	LV,	MD,	MG		MK,	MN,	MW,	MX,	NO,	NZ,	PL,	
		PT.	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL	,	TJ,	TM,	TR.	TT,	UA,	UG,	UZ,	
		VN.	YU.	ZW,	AM,	AZ,	BY,	KG.	KZ,	MD	i,	RU,	TJ,	TM					
	RW:	GH,	ΚE,	LS,	MW,	SD,	SZ,	UG,	ZW,	AT	,	BE,	CH,	DE,	DK,	ES,	FI,	FR,	
		GB,	GR,	IE,	IT,	LU,	MC,	NL,	PT,	SE		BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	
		GN,	ML,	MR,	ΝE,	SN,	TD,	TG											
CA	2262 9738	434			AA		1998	0205		CA	19	97-2	2262	434		1	9970	729	
ΑU	9738	971			A1		1998	0220		υA	19	97-:	3897	1		1	9970	729	
ZA	9706 9342	730			A		1999	0729		ZΑ	19	97-	6730			1	9970	729	
EΡ	9342	74			A1		1999	0811		EΡ	19	97-9	9362	59.		1	9970	729	
	R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR		ΙT,	LI,	LU,	NL,	SE,	MC,	PT.	
	1239 9902	ΙE,	FI																
CN	1239	474			A		1999	1222		CN	19	97-	1982	5 B		1	9970	729	
TR	9902	325			T2		2000	0221		TR	19	99-9	9902	325		1	9970	729	
TR	9902	326			T2		2000	0522		TR	19	99-9	9902	326		1	9970 9970 9970	729	
ΝZ	3339	51			A		2000	0929		NZ	19	97-	3339	51		1	9970	729	
BR	9710	637			A.		2000	1031		BR	19	97-	1063	7		1	9970	729	
JΡ	2001	5124	16		T2		2001	0821									9970		
RU	2195	443			C2		2002	1227		RU	19	99-:	1045	27		1	9970	729	
TW	5203	60			В		2003	0211		TW	19	97-1	3611	0851		1	9970	729	
МО	9902 9902 3339 9710 2001 2195 5203 9900 3141	399			A		1999	0329		NO	19	99-:	399			1	9990	128	
МО	3141	43			BI		2003	0203											
KR	2000	0297	23		A		2000	05Z5		KR	19	99~	7008	26		1	9990	130	
LITY	2000 APP	LN.	INFO	. :						US	19	96+1	5901	11		A 1	9960	731	
										wo	10						9970		

OTHER SOURCE(S):

PF

MARPAT 128:167354

ANSWER 5 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

AB The title compds. [I (A = (un)substituted C6-10 aryl; D = up to 8 carbon atoms alkyl which is substituted by hydroxy; E, L = (un)substituted up to 8 carbon atoms alkyl; L = (un)substituted C6-10 aryl; T = R7X, R8C(R8)(R10); R7, R8 = cycloalkyl, aryl, etc.; R9, R10 = H, halo, N3, etc.), II (R1 = cycloalkyl, aryl, etc.; R9, R10 = H, halo, N3, etc.), II (R1 = cycloalkyl, aryl, etc.); L1 (R1a, R1b = CF3, C1-10 alkyl, C1-10 alkenyl, etc.; R2 = C1-10 alkyl, C1-10 alkenyl, etc.; R3 = OH, CF3, C1-6 alkanoyl, etc.; R7 = (un)substituted heteroaryl, aryl), IVI, useful for the inhibition of cholesterol ester transfer proteins (CETP) (I), for the treatment of hyperlipoproteinemia (II), and for inhibition of the glucagon receptor, leading to treatment of glucagon-mediated conditions such as diabetes (III-IV), were prepared Thus, reduction of Etc., 6-diisopropyl-4-(4-flucrophenyl)-3-[(4-flucrophenyl)-chormethyl)pyridine-5-carboxylate (preparation described) with LiAlH4 in THF

afforded 69% I [A = 4-FC6H4; D = CH2OH; E = L = iPr; T = 4-FC6H4CH2].

L3 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2005 ACS ON STN ACCESSION NUMBER: 1998:55679 CAPLUS DOCUMENT NUMBER: 128:127938

128:127938
Antiatherosclerotic 6-(hydroxymethylethyl)pyridines
Fey, Peter; Angerbauer, Rolf; Schmidt, Delf; TITLE: INVENTOR(S):

Bischoff. Hilmar; Kanhai, Wolfgang; Radtke, Martin; Karl,

Hilmar; Kanhai, Wolf Wolfgang Bayer A.-G., Germany Ger. Offen., 26 pp. CODEN: GWXXBX Patent German

PATENT ASSIGNEE(S): SOURCE:

DOCUMENT TYPE:

LANGUAGE:

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

	PAT	FENT	NO.			KIN	D	DATE		AP	PLICAT	ION	NO.		D.	ATE	
							-								-		
	DE	1962	7420			A1		1998	0115	DE	1996-	1962	7420		1	9960	708
	EP	8184	147			A1		1998	0114	EP	1997-	1102	76		1	9970	624
	EP	8184	47			В1		2004	0526								
		R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB, G	R, IT,	LI,	·LU,	NL,	SE,	MC,	PT,
			IE,	FI													
	AT	2678	107			E		2004	0615	AT	1997-	1102	76		1	9970	624
	PT	8184	47			т		2004	0831	PT	1997-	1102	76		1	9970	624
	ES	2219	711			тз		2004	1201	ES	1997-	1102	76		1	9970	624
	US	5849	749			A		1998	1215	US	1997-	8836	95		1	9970	627
	JP	1006	7744			A2		1998	0310	JP	1997-	1920	10		1	9970	703
	CA	2209	550			AA		1998	0108	CA	1997-	2209	550		1	9970	704
RIO	RIT	Y APE	LN.	INFO	. :					DE	1996-	1962	7420	,	<b>A</b> 1	9960	708

OTHER SOURCE(S): MARPAT 128:127938

AB Title compds. I [R1, R2 = H, Me] were prepared for use in treatment of atherosclerosis (no data). Thus, (3R,55,1'S)-I [R1 = Me, R2 = H] was prepared from (R)-Me3CS:Ph2OCH2CHMCOCH2CO2Me and 4-FCGH4CH:C(COZMe) COCCHMe2 in 10 steps.

1 19906-08-0P 189060-14-8P
RU: RCT (Reactant): SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (Preparation of antiatherosclerotic dihydroxy(hydroxymethylethyl)pyridinehex

L3 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 202857-49-6 CAPLUS
CN 3-Pyridinecarboxylic acid,
4-(4-fluorophenyl)-5-(1-methoxyethyl)-2,6-bis(1-methylethyl)-, methyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

enoates) 189060-08-0 CAPLUS

Absolute stereochemistry.

RN 189060-14-8 CAPLUS
CN 3-Pyridinecarboxylic acid,
6-{2-{[(1,1-dimethylethyl)diphenylsilyl)oxy}-1methylethyl)-4-{4-fluorophenyl}-5-(methoxymethyl)-2-(1-methylethyl)-,
methyl ester, (\$)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

(Continued)

ANSWER 7 OF 13 CAPLUS COPYRIGHT 2005 ACS ON STN SSION NUMBER: 1997:193432 CAPLUS MENT NUMBER: 126:287522 ACCESSION NUMBER: DOCUMENT NUMBER: 140:287527
Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isoenzymes involved Boberg, Michael: Angerbauer, Rolf; Fey, Peter: TITLE: AUTHOR (S): Wolfgang K.; Karl, Wolfgang; Kern, Armin; Ploschke, Juergen; Radtke, Martin Department of Drug Metabolism and Isotope Chemistry, Pharma Product Development, Bayer AG, Wuppertal, D-42096, Germany Drug Metabolism and Disposition (1997), 25(3), CORPORATE SOURCE: SOURCE: 321-331 CODEN: DMDSAI; ISSN: 0090-9556 Williams & Wilkins PUBLISHER: ISHEM: Williams & Wikins
MENT TYPE: Journal
UAGE: English
Biotransformation of cerivastatin, a new cholesterol-lowering drug, by
human liver microsomes was investigated using the 14C-labeled drug.
Metabolite profiles were established by HPLC and structures of DOCUMENT TYPE: LANGUAGE: Metabolite profiles were established by HPLC and structures of metabolites were elucidated. Two metabolic pathways were equally important, demethylation of the benzylic Me ether and hydroxylation at one Me group of the 6-iso-Fr substituent. The product of combined hydroxylation and demethylation was observed as a minor metabolite. During sample preparation the lactone forms of both primary metabolites were isolated in small amts. Detailed structural anal. by NNR and LC-ESI-MS showed that hydroxylation occurred with high regio- and stereoselectivity. The proposed structures were confirmed by chemical synthesis of enantiomerically pure reference compds. were confirmed by chemical synthesis of enantiomerically pure reference compds.

Microsomes from a human lymphoblastoid AHH-1 cell-line, stably expressing CYP 3A4, catalyzed the demethylation reaction. Upon incubation of cerivastatin with human liver microsomes in the presence of the specific CYP 3A inhibitor TAO, both hydroxylation and demethylation were considerably reduced. This indicates that CYP 3A enzymes play a major role in cerivastatin metabolism

IT 18966-08-01-09 18960-14-99

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(cytochrome P 450 isoenzymes and pathways in metabolism of cerivastatin by
human liver microsomes in vitro)

RN 18966-08-0 CAPIUS

CN 3,5-Pyridinedicarboxylic acid, 2-[2-[1,1-dimethylethyl]-dipenylsilyl]oxy
]-1-methylethyl]-4-(4-fluorophenyl)-6-(1-methylethyl)-, dimethyl ester, (S)-(SCI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1993:428008 CAPLUS
DOCUMENT NUMBER: 119:28008
7-(polysubstituted pyridyl)-6-heptenoates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis
INVENTOR(S): Angerbauer, Rolf: Fey, Peter: Huebsch, Walter: Philipps, Thomas; Bischoff, Hilmar: Petzinna, Dieter: Schmidt, Delf: Thomas, Guenter
PATENT ASSIGNEE(S): Bayer A.-G., Germany
U.S., 63 pp. Cont.-in-part of U.S. 5,006,530.
CODEN: USXXXAM
Patent DOCUMENT TYPE: English FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5169857	A	19921208	US 1990-627086	19901213
DE 3801406	A1	19890727	DE 1988-3801406	19880120
DD 283400	A5	19901010	DD 1989-325090	19890117
US 5006530	A	19910409	US 1989-298549	19890117
ZA 8900429	A	19900228	ZA 1989-429	19890119
HU 52053	A2	19900628	HU 1989-5141	19890119
US 5401746	A	19950328	US 1992-916928	19920720
PRIORITY APPLN. INFO.:			DE 1988-3801406	19880120
			IT 1988-21317	19880711
			US 1989-298549	2 19890117
			US 1990-627086	3 19901213

CASREACT 119:28008; MARPAT 119:28008

OTHER SOURCE(S):

Substituted pyridine derivs., (E)-3,5-dihydroxy-7-(4-phenyl-3-pyridyl)-6-heptenoates, are claimed. The use of these compds. for the treatment of hyperlipoproteinemia, lipoproteinemia, or arteriosoclerosis is claimed. Also claimed is Me (E)-erythro-7-[2-(4-fluorophenyl)-4-isopropyl-5-(methoxymethyl)-6-methyl-3-pyridyl]-3,5-dihydroxy-6-heptenoate (I). I AB

ANSWER 7 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

189060-14-8 CAPLUS To Solve Service Service

Absolute stereochemistry.

Ph

L3 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN (Continued) prepd. from Et 2-(4-fluorophenyl)-5-(methoxymethyl)-6-methyl-3-pyridinecarboxylate. The compds. thus prepd. are inhibitors of cholesterol synthesis (no data).

IT 124864-26-2P
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, as anticholesteremic and antiarteriosclerotic)
RN 124864-26-2 ACPLUS
CN 3-Pyridinecarboxylic acid, 4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-, ethyl ester (9CI) (CA INDEX NAME)

ΙŤ 124894-15-1P IT 12494-15-1P

RL: SPM (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for
dihydroxy(phenylpyridyl)heptenoate
(anticholesteremic and antiarteriosclerotic))

RN 124894-15-1 CAPIUS
CN 3-Pyridinecarboxylic acid, 5-(ethoxymethyl)-4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-, ethyl ester (9CI) (CA INDEX NAME)

IT 124863-79-2 124863-88-3 RCT (Reactant): RACT (Reactant or reagent)
(reactant for dihydroxy(phenylpyridyl)heptenoate (anticholesteremic antiarteriosclerotic)) RN 124863-79-2 CAPIUS
CN 3,5-Pyridinedicarboxylic acid,
4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-,
diethyl ester (9CI) (CA INDEX NAME)

ANSWER 8 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

124863-88-3 CAPLUS 3-Pyridinecarboxylic acid, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[(phenylmethoxy)methyl]-, ethyl ester (9CI) (CA INDEX NAME)

$$Ph-CH_2-O-CH_2$$
 $i-Pr$ 
 $N$ 
 $Pr-i$ 

ANSWER 9 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN (Continued) CHMe2, R1R3 = bond, R2 = H, R4 = 4-FC6H4, R5 = Me) were obtained. 124863-97-2PL3 IT

L3 ANSWER 9 OF 13 CAPILUS COPYRIGHT 2005 ACS on STN ACCESSION NUMBER: 1991:207045 CAPILUS DOCUMENT NUMBER: 114:207045 TITLE: Iminomethylpyridineheptenoates

114:207045
Iminomethylpyridineheptenoates
Angerbauer, Rolf; Fey, Peter; Huebsch, Walter;
Philipps, Thomas; Bischoff, Himlar; Petzinna, Dieter;
Schmidt, Delf
Bayer A.-G., Germany
Eur. Pat. Appl., 35 pp.
CODEN: EPXXDW
Patent INVENTOR(S):

PATENT ASSIGNEE(S):

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PA'	TENT NO				KIN		DATE		Al	P	LICA	TI	ON	NO.			DATE
										-							
	411420				A2			0206	E	•	1990	-1	140	15			1990072
EP	411420				A.3		1991	1106									
	R: A	т,	BE,	CH,	DE,	DK,	, ES,	FR,	GB, C	ξŔ	, IT	٠,	LI,	LU,	NL,	SI	E
DE	392563	6			A1		1991	0207	DI	3	1989	-3	925	636			1989080
US	506484	1			А		1991	1112	US	;	1990	-5	580	129			1990072
AU	905997	4			A1		1991	0207	AI	3	1990	-5	997	4			1990073
AU	622342				B2		1992	0402									
CA	202242	3			AA		1991	0204	c	١.	1990	-2	022	423			1990080
JP	030666	68			A2		1991	0322	JI	,	1990	-2	025	91			1990080
DD	298919				A5		1992	0319	DI	)	1990	-3	431	93			1990080
ZA	900607	θ			А		1991	0529	2.1	١.	1990	-6	078	:			1990080
HU	56066				A2		1991	0729	н	,	1990	-4	884	ı			1990080
	59906				A2		1992	0728	н	,	1991	-1	809	•			1990080
	518389				A		1993	0202	U	3	1991	-6	872	72			1991041
RIORIT														636		A.	1989080
											1990					_	1990072

OTHER SOURCE(S): CASREACT 114:207045; MARPAT 114:207045

CHR1CH2CR2 (OH) CH2CO2R3

3-Hydroxy-3-methylglutaryl-CoA-inhibiting and anticholesteremic (no data) pyridines I [X = CH2CH2, CH:CH; R = alkyl, aryl; Rl = OH, R2 = H, alkyl, R3 = H, alkyl, phenylalkyl; R1 = bond; R4 = (un)substituted aryl; R5 = (un)substituted aryl, alkyl; R6 = cycloalkyl, (un)substituted aryl, alkyl; R6 =

were prepared in multiple steps. I  $\{X = E-CH: CH, R = R6 = CHMe2, R1 = R6\}$ 

R2 = H, R3 = Me, R4 = 4-FC6H4, R5 = Me, PhCH2, Me3C; X = E-CH:CH, R = R6

L3 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN ACCESSION NUMBER: 1991:164010 CAPLUS DOCUMENT NUMBER: 114:164010 Preparation of pyridine dimeval 114:164010
Preparation of pyridine dimevalonolactone and analogs as HMG-CoA reductase inhibitors
Chucholowski, Alexander
Warner-Lambert Co., USA
U.S., 11 pp.
CODEN: USXXAM
Patent
English

INVENTOR(S):
PATENT ASSIGNEE(S):
SOURCE:

DOCUMENT TYPE:

LANGUAGE:

English FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE US 4950675 PRIORITY APPLN. INFO.: 19900821 US 1988-287497 US 1988-287497 19881221 19881221 А

OTHER SOURCE(S): CASREACT 114:164010; MARPAT 114:164010

$$\bigcap_{Q} \bigcap_{R^2} \bigcap_{N-Y} \bigcap_{Q} \bigcap_{N-Y} \bigcap_{Q} \bigcap_{N-Y} \bigcap_{Q} \bigcap_{N-Y} \bigcap_{Q} \bigcap_{N-Y} \bigcap_{Q} \bigcap_{N-Y} \bigcap_{N-Y}$$

AB The title compds. [I: X = CH2CH2, CH:CH: R1, R2 = Cl-6 alkyl, CF3, cyclopropyl, cyclohexyl(methyl), NR4R5; R3 = any of definitions for R1,R2,

(, (un)substituted Ph or PhCH2; R4, R5 = H, Cl-4 alkyl, R4R5N to close a (hetero)cyclyl moiety Q-Q2; Y = H, Cl-4 alkyl; n = 0-51 or the corresponding N-oxides, useful as cholesterol biosynthesis inhibitors, were prepared I (R1 = R2 = Me2CH, R3 = 4-FC6CH4, X = CH:CH) (II) was used prepared in 10 steps via pyridinedicarboxylate III (preparation by cyclocondensation of

Page 9

- ANSWER 10 of 13 CAPLUS COPYRIGHT 2005 ACS on STN (Continued) 4-FC6H4CHO, MeZCHCOCH2COZMe, and NH4OH in refluxing MeOH). In a cholesterol biosynthesis inhibition assay in rats, II at 1.0 mg/kg gave 651 inhibition in vivo. 122549-42-2P
- IT 122549-42-2P
  RL: RCT (Reactant): SPN (Synthetic preparation); PREP (Preparation); RACT
  (Reactant or reagent)
  (preparation and reaction of, in preparation of HMG-CoA reductase inhibitor)
  RN: 122549-42-2 CAPUUS
  CN: 3,5-Pyridinedicarboxylic acid,
  4-(4-fluorophenyl)-2,6-bis (1-methylethyl)-,
  dimethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN ACCESSION NUMBER: 1990:158057 CAPLUS DOCUMENT NUMBER: 112:158057 Pyridinediheptanoic acid deriv. Pyridinediheptanoic acid derivatives useful as reductase inhibitors, their preparation and intermediates, and pharmaceuticals containing them Angerbauer, Rolf: Fey, Peter: Ruebsch, Walter: Philipps, Thomas: Bischoff, Hilmar: Petzinna, Dieter: Schmidt, Delf: Thomas, Guenter Bayer A.-G., Fed. Rep. Ger. Eur. Pat. Appl., 60 pp. CODEN: EPXXDW Patent
German INVENTOR (S): PATENT ASSIGNEE(S): SOURCE: DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION: German

PATENT NO	. KIN	D DATE	APPLICATION NO.		DATE
EP 325129	A2	19890726	EP 1989-100249		19890109
EP 325129	A3	19901219			
EP 325129	B1	19940907			
DE 380144	0 A1	19890803	DE 1988-3801440		19880120
NO 890004	6 A	19890721	NO 1989-46		19890105
ES 205834	3 T3	19941101	ES 1989-100249		19890109
US 496868	9 A	19901106	US 1989-298453		19890117
IL 88971	A]	19930708	IL 1989-88971		19890117
FI 890025	7 A	19890721	DE 1988-3801440 NO 1989-46 ES 1989-100249 US 1989-298453 IL 1989-28971 FI 1989-257 DD 1989-325115 AU 1989-28613		19890118
FI 92195	В	19940630			
FI 92195	C	19941010			
DD 283379	A5	19901010	DD 1989-325115		19890118
AU 892861	3 A1	19890720	AU 1989-28613		19890119
AU 614810	B2 2 A	19910912			
DK 890023	2 A	19890721	DK 1989-232		
ZA 890042	A 8	19891025	ZA 1989-428		19890119
JP 020014	78 A2	19900105	JP 1989-8769		19890119
HU 50775	8 A 78 A2 A2	19900328			
CN 103471	6 A	19890816	CN 1989-100406		19890120
		19921222	US 1990-564502		19900808
		19951128	US 1992-950623		19920924
US 550205	7 A	19960326	US 1993-92655		19930714
PRIORITY APPLN	. INFO.:		DE 1988-3801440	A	19880120
			IT 1988-21587	А	19880729
			US 1989-298453	A3	19890117

OTHER SOURCE(S):

CASREACT 112:158057

us 1990-587700

B3 19900925

ANSWER 11 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

The title compds. I [R1 = (un)substituted aryl, heteroaryl; R2 = cycloalkyl, (un)substituted alkyl; R3 = H, cycloalkyl, (un)substituted alkyl, (heterolaryl; X = CH2CH2, CH:CH: A = CH(OH)CH2CR4(OH)CH2CCR5 or lactone ring Q; R4 = H, alkyl; R5 = H, alkyl, aryl, aralkyl, cation) were prepared as antihypercholesterolemics, specifically as inhibitors of Cra

prepared as anthypethnistectuates, prepared as anthypethnistectuates, prepared as anthypethnistectuates, preductase. Thus, condensation of 4-FC6H4CHO with Me2CHCOCH2COZET (82.3%) and of the resulting enone with Me2CH(NH2)C:CHCO2ET (23.4%) gave dihydropyridinedicarboxylate II. By a sequence of aromatization (87.9%), reduction to the diol (66.7%), oxidation to the dialdehyde (85.3%),

Wittig-type homologation (50%), reaction with the diamion of MeCOCH2CO2Me (53.6%),

NaBH4 reduction, II was converted to erythro-(E)-III (R = Me). At 8

mg/kg/dsy orally in beagles, the salt erythro-(E)-III (R = Na) lowered serum cholesterol by 22.4% in 2 wk. IT 124863-79-2P (Synthetic preparation); PREP (Preparation) IT 124863-79-2P

RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of antihypercholesterolemic)

RN 124863-79-2 CAPLUS

CN 3,5-Pyridinedicarboxylic acid,
4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-,
diethyl eater (9CI) (CA INDEX NAME)

ANSWER 11 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

L3 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1990:55616 CAPLUS

ITITLE: Preparation of 7-(4-aryl-3-pyridyl)-3,5-dihydroxy-6-heptenoates and analogs as hypocholesterenics

Angerbauer, Rolf: Fey, Peter: Ruebsch, Walter: Philipps, Thomas; Bischoff, Hilmar: Petzinna, Dieter: Schnidt, Delf: Thomas, Guenter

PATENT ASSIGNEE(S): Bayer A.-G., Fed. Rep. Ger.

SOURCE: EU. Pat. Appl., 132 pp.

CODEN: EFEXXDW

DOCUMENT TYPE: LANGUAGE: Path German

FAMILY ACC. NUM. COUNT: 2

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT NO.		KIN		APPLICATION NO.		DATE
ED 325130				EP 1989-100250		19890109
EP 325130		A3	19901205			
EP 323130		B1	20031105			
R: AT	, BE,	CH, DE,	ES, FR, GB,	GR, IT, LI, NL, SE		
DE 3801406				DE 1988-3801406		
NO 8900047		A	19890721	NO 1989-47		19890105
NO 177005		В	19950327 19950705			
NO 177005		С	19950705			
EP 1123924		Al	20010816	EP 2001-109309		19890109
R: AT	, BE,	CH, DE,	ES, FR, GB,	GR, IT, LI, NL, SE		
EP 1123925		A1	20010816	EP 2001-109310		19890109
R: AT	, BE,	CH, DE,	ES, FR, GB,	GR, IT, LI, NL, SE		
						19890109
ES 2210221		Т3	20040701	AT 1989-100250 ES 1989-100250		19890109
CN 1034364		A	19890802	CN 1989-100326 DD 1989-325090 FI 1989-258		19890117
CN 1055684		В	20000823			
DD 283400		A5	19901010	DD 1989-325090		19890117
FI 8900258		A	19890721	FI 1989-258		19890118
FI 93007		В	19941031	•		
FI 93007		С	19950210	· ·		
CA 1340798		Al	19991026	CA 1989-588502		19890118
AU 8928617		A1	19890720	AU 1989-28617		19890119
AU 642127		B2	19931014			
DK 8900233		A	19890721	DK 1989-233		19890119
JP 0121697	4	A2	19890830	AU 1989-28617 DK 1989-233 JP 1989-8770		19890119
JP 2558344		B2	19961127			
ZA 8900429		A	19900228 19900328	ZA 1989-429		
HU 50776		A2	19900328	HU 1989-214		19890119
HU 210727		B A2	19950728			
HU 52053		A2	19900628 19980417	HU 1989-5141 KR 1989-550 CN 2000-102357		19890119
KR 132432		B1	19980417	KR 1989-550		19890119
CN 1274719		A	20001129	CN 2000-102357		20000217
ORITY APPLN.	INFO.	:		DE 1988-3801406	A	19880120
				IT 1988-21317	A	19880711
				EP 1989-100250	А3	19890109

ANSWER 12 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

The title compds. [I; A = {un}substituted aryl, heteroaryl; B = cycloalkyl, {un}substituted alkyl; D,E = H, cyano, NO2, cycloalkyl, {un}substituted alkyl, heteroaryl, aryl, etc.; DE = COZ(CHZ)m, WZCR13R14(CHZ)m; R = CH(OH)CHZCAZ1(ON)CHZCOZR2Z, Q; R13, R14 = {un}substituted aryl, aralkyl, heteroaryl; R21 = H, alkyl; R22 = H,

aryl, aralkyl, cation; W = CO, CHOH; X = CH2CH2, CH:CH; Z = O, S, CH2, (un)substituted imino; m = 1-3] were prepared Thus, 4-FC6H4CH:C(COCHME2)COZEt (preparation given) was refluxed 18 h with MeZCHC(NH2):CHOCZEt in EtOH and the product stirred 1 h with DDQ (oxidizing agent) in CH2Cl2 to give phenylpyridinedicarboxylate II (R1 = R2 = COZEt) which was converted in 4 steps to II (R1 = PhCH2CCH2, R2 = CHO). The latter was refluxed in THF with d1-Et [2-(cyclohexylamino)vinyl]phosphonate which had been treated with NAH and

product refluxed with (CO2H)2 in PhMe to give II [R2 = (E)-CH:CHCHO]

was condensed with MeCOCH2CO2Me which had been treated with 2 equivalent

NaH to give, after reduction, title compound II [R1 = PhCH2OCH2, R2 = erythro-(E)-CH:CHCH:OH)CH2CH(OH)CH2CO2Me] which gave 66% reduction of many control of the control of

serum
cholesterol in dogs receiving 8 mg/kg orally daily.

124663-79-2P 124653-88-3P 124654-62-2P
124994-15-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and reaction of, in preparation of hypocholesteremics)

RN 124863-79-2 CAPLUS
CN 3,5-Pyridinedicarboxylic acid,
4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-,
diethyl ester (9CI) (CA INDEX NAME)

ANSWER 12 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

124863-88-3 CAPLUS

3-Pyridinecarboxylic acid, 4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[(phenylmethoxy)methyl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 124864-26-2 CAPLUS
CN 3-Pyridinecarboxylic acid,
4-(4-[luorophenyl]-5-(methoxymethyl)-2,6-bis(1-methylethyl)-, ethyl ester (9CI) (CA INDEX NAME)

124894-15-1 CAPLUS
3-Pyridinecarboxylic acid, 5-(ethoxymethyl)-4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-, ethyl ester (9CI) (CA INDEX NAME)

ANSWER 12 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L3 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1989:533996 CAPLUS
DOCUMENT NUMBER: 11:133996

6-[[(Substituted)pyridin-3-yl]alkyl]- and alkenyl]tetrahydro-4-hydroxypyran-2-ones and open

acid derivatives, useful as inhibitors of cholesterol biosynthesis, and their preparation and

pharmaceutical

INVENTOR (S):

PATENT ASSIGNEE (S): SOURCE:

DOCUMENT TYPE: LANGUAGE:

LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

ATEN	rı	NFORMAT	ION:												
	PA1	TENT NO.			KIN	•	DATE		AP	PLICA	TION	NO.			DATE
						-									
1	ΕÞ	306929			A2		1989	0315	EF	1988	-114	629			19880907
1	ΕÞ	306929			A3		1990	0207							
		R: AT	, BE,	CH,	DE,	ES,	FR,	GB,	GR, I	T, LI	, LU	, NL,	SE		
	US	4906624			A		1990	0306	ŲS	1988	-226	190			19880802
	ZΑ	8806098			A		1990	0425	Z.A	1988	-609	В			19880817
	ΑU	8821412			A1		1989	0309	AU	1988	-214	12			19880818
	ΑU	620559			B2		1992	0220		•					
	FI	8804080			А		1989	0309	FI	1988	-40B	0			19880905
1	DK	8804974			A		1989	0309	DK	1988	-497	4			19880907
1	NO	8803974			А		1989	0309	NO	1988	-397	4			19880907
	JΡ	0112126	6		A2		1989	0512	JP	1988	-222	593			19880907
1	US	4997837			А		1991	0305	US	1989	-417	996			19891006
RIOR	ITY	APPLN.	INFO	. :					US	1987	-941	98	F	١.	19870908

US 1988-226190 A 19880802

OTHER SOURCE(S):

CASREACT 111:133996; MARPAT 111:133996

ANSWER 13 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

HO-CH=CH-CH<sub>2</sub> 
$$\stackrel{\circ}{\underset{i-Pr}{\bigvee}}$$
  $\stackrel{\circ}{\underset{r-ome}{\bigvee}}$   $\stackrel{\circ}{\underset{r-ome}{\bigvee}}$ 

ANSWER 13 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Title pyranomes I and acids II [X = CH2CH2, CH:CH: Rl, R4 = alkyl, CF3,
Cl, Br, certain cycloalkyl, heterocyclyl, or anino, (un)substituted Ph or
PhCH2: also R1 = cyano, OR, SONR where n = 0-2 and R = alkyl,
(un)substituted Ph or PhCH2: R2 = H, alkyl, CF3, cyclopropyl, CH2OH, Cl,
Br, certain heterocyclyl or anino, (un)substituted Ph: R3 = H, alkyl,
cyano, NO2, (di)(alkyl)amino, Ph, CO2H, alkoxy- or phenoxycarbonyl,
N,

CH2OH,
Various amido; trans racemate of tetrahydropyran moiety] and their
N-oxides, alkyl esters, and pharmaceutically acceptable salts are

prepared
as hypocholesterolemics and hypolipidemics. Cyclocondensation of
(E)-PhCH:CHCHO with Me(H2N)C:CHCOZEL, aromatization of the resultant
dihydropyridine, reduction of the ester with Dibal, and reoxidn. with
(COC1)2/Me2So gave 2-methyl-4-phenyl-3-pyridinecarboxaldehyde. Wittig
reaction of this with Ph3P:CHCOZMe, reduction and reoxidn. as above, and
condensation of the aldehyde with MeCOCH2COZEt gave (E)-Et
5-hydroxy-7-(2-methyl-4-phenyl-3-pyridinyl)-3-oxo-6-heptenoate.
Treatment

Treatment
of the latter with Et3B.THF/NaBH4/H2O2, saponification with NaOH in
aqueous THF, and
lactonization in refluxing PhMe gave I (X = CH:CH, R1 = Me, R2 = R3 = H,
R4 = Ph) (III). At 1.5 mg/kg orally in rats, III gave 55% inhibition of
cholesterol biosynthesis.
IT 122549-42-2 122549-43-3
RL: RCT (Reactant): RACT (Reactant or reagent)
(reaction of, in preparation of hypocholesterolemic pyridinylalkyland

and
-alkenyltetrahydrohydroxypyranones and derivs.)
RN 122549-42-2 CAPLUS
CN 3,5-Pyridinedicarboxylic acid,
4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-,
dimethyl ester (9CI) (CA INDEX NAME)

RN 122549-43-3 CAPLUS CN 3-Pyridinecarboxylic acid, 4-(4-fluorophenyl)-5-(3-hydroxy-2-propenyl)-2,6-bis(1-methylethyl)-, methyl ester (9CI) (CA INDEX NAME)

=> fil reg COST IN U.S. DOLLARS SINCE FILE TOTAL SESSION ENTRY FULL ESTIMATED COST 66.47 228.01 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION CA SUBSCRIBER PRICE -9.49 -9.49

FILE 'REGISTRY' ENTERED AT 16:27:16 ON 16 APR 2005 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 APR 2005 HIGHEST RN 848629-85-6 DICTIONARY FILE UPDATES: 15 APR 2005 HIGHEST RN 848629-85-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at: http://www.cas.org/ONLINE/DBSS/registryss.html

Uploading C:\Program Files\Stnexp\Queries\10-624659z1.str

```
chain nodes :
14 15 16 17 18 19 20 21 22 23 24 25 26
                                              27
                                                 28
                                                     29
                                                         30
                                                            34
                                                                37 38 39
ring nodes :
                     9 10 11 12
1 2 3 4 5 6 7 8
chain bonds :
                               14-15 14-16 17-18 17-19 21-22 21-30 22-23
2-14 3-34 4-7 5-44 6-17 10-20
22-24 25-26 25-27 28-29 37-38 38-39
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
3-34 5-44 22-23 22-24 25-26 25-27 28-29 38-39
exact bonds :
2-14 4-7 6-17 10-20 14-15 14-16 17-18 17-19 21-22
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11
isolated ring systems :
containing 1 : 7 :
```

G1:[\*1]

G2:0,[\*2],[\*1],[\*3]

Match level:
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS
28:CLASS 29:CLASS 30:CLASS 34:CLASS 37:CLASS 38:CLASS 39:CLASS 44:CLASS

10/624659 Page 15

L4 STRUCTURE UPLOADED

=> d

L4 HAS NO ANSWERS

L4 STF

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s 14 ful

FULL SEARCH INITIATED 16:27:34 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 558 TO ITERATE

100.0% PROCESSED 558 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

L5 0 SEA SSS FUL L4

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION FULL ESTIMATED COST 161.33 389.34 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION CA SUBSCRIBER PRICE 0.00 -9.49

STN INTERNATIONAL LOGOFF AT 16:27:49 ON 16 APR 2005